Sunset Naturals Recall, Cancer 'Supplement' Warning: Health & Wellness Industry News Roundup

  
Generate a summary of this article
Listen to this article
Beta

Sunset Natural's mandated recalls ongoing; PNC-27 'supplement' contaminated with bacteria; FTC Chairwoman Ramirez retiring; and more news in brief.

Sunset Natural Products Inc. recalls 165 separate products in compliance with a 2015 consent decree that required it to cease operations and receive FDA clearance before resuming manufacturing and distributing supplements. The agency's Jan. 4 recalls list includes the Miami firm's FDA-mandated recall of all supplements it manufactured, prepared, processed, packed, labeled, held and/or distributed from April 2014 through the day it entered the decree to settle a complaint the Department of Justice filed in US District Court for the Southern District of Florida. According to the FDA database, supplements marketed under brands such as Super Vita Green,Karma, Body Shape, Triflex, Bioxtron and Via Sex were recalled in quantities from several hundred to nearly 30,000 bottles or as many as 3.9m capsules, but also in unknown quantities for numerous items. The recalls started in October 2015 and are ongoing, according to FDA.

FDA inspected Sunset Natural’s facility in 2012 and submitted a warning letter on GMP violations in 2013 before finding the...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from United States

Different Name, Same Contamination, Recall Problems For US Homeopathic Nasal Spray Firm

Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.

Lauder’s Outgoing CFO Breaks Down Global Prestige Beauty, Firm’s Transition Moment

 
• By Eileen Francis

Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.

Perrigo Securities Class-Action Settlement Awards Attorneys’ Fees, Expenses Lower Than Requested

 
• By Malcolm Spicer

Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.

More from North America

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process. 

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 
• By Malcolm Spicer

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 
• By Malcolm Spicer

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.